Analysis of global mRNA drug industrialization dynamics
10.16438/j.0513-4870.2023-0537
- VernacularTitle:全球mRNA药物产业化动态浅析
- Author:
Chang-chun ZHAO
1
;
Hai HUANG
1
;
Yong-jun GU
1
;
Deng-gang WANG
1
;
Xiang-rong SONG
1
,
2
Author Information
1. Chengdu WestGene Biopharma Co., Ltd., Chengdu 610218, China
2. State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China
- Publication Type:Research Article
- Keywords:
mRNA drug;
GMP production;
industry chain;
value chain;
core competitiveness
- From:
Acta Pharmaceutica Sinica
2023;58(8):2353-2363
- CountryChina
- Language:Chinese
-
Abstract:
The successful development and application of mRNA COVID-19 vaccine fully illustrated the great potential and application prospect of mRNA technology in the field of biomedicine. Currently, many companies worldwide are developing drugs and vaccines based on mRNA technology for the prevention and treatment of various diseases. It can be foreseen that with the continuous launch of mRNA drugs, commercial GMP production capacity matching them is also urgent. The optimization of production processes, intelligent manufacturing and other risk control strategies, as well as the control of industrialization costs, will help improve the core competitiveness of mRNA innovative drug development. In view of this, this article will provide an overview of the global production process of mRNA drugs and the progress of related GMP production dynamics, sort out the key chain points of the mRNA industry chain, explore the construction of the mRNA pharmaceutical enterprise value chain and the formation of core competitiveness, and provide reference and reference for the research and development of innovative mRNA drugs and high-quality development in China.
